Cures for HIV and blurred vision and using cosmic rays to monitor nuclear waste drums are on our list of recent promising university spinouts.
CasInvent Pharma’s approach is aimed at three forms of cancer rather than just one, with leukaemia, lymphoma and solid tumours all in its sights.
Non-recyclable plastics making asphalt more sustainable and a vaccine to save the honeybee are just two of 10 inventions that caught our eye.
Phil Clare has joined Queen Mary Innovation as chief executive, having previously worked for University of Oxford since 2006.
Could we save the environment one parcel at a time? Politecnico di Milano’s packaging technology spinout Voidless hopes so.
Sean Fielding has worked for University of Exeter for nearly three decades, during which time his board memberships included ATTP, SETsquared and PraxisAuril.
Spinouts working on ketamine-based therapeutics, regenerative medicines for dogs and better sleep are among those that caught our eye this month.
Maxine Ficarra has been with the organisation since its original incarnation of Praxis Courses and CEO since it became PraxisAuril in 2017.
These are the spinouts that caught our eye over the past month. Here's why they should be on your radar, too.
Oxford Science Enterprises now has just over $1bn under management and already boasts a portfolio of more than 80 University of Oxford spinouts.
Cambridge Enterprise has put cash into CardiaTec Biosciences in a pre-seed round that marks the inaugural deal for Laidlaw Scholars Ventures.
Oxford Quantum Circuits' series A round is already among the largest for a European quantum company and could still go higher.
IP Group has established Kiko Ventures to build out its existing $215m cleantech portfolio and will invest $245m over the next five years.
The energy sector hasn't had a technology breakthrough for a decade. But Engie New Ventures' Johann Boukhors is excited about the potential for green hydrogen and methane.
Failure rates are high for VC-backed companies, and corporate-backed startups are not exempt. But which have been the biggest recent flops that left corporate investors licking their wounds?
It is hard to build an agile, innovative startup inside a big corporation. But not impossible. Setting boundaries and defining your terms carefully will help minimise the risk of failure.
Catherine Zhou, who heads up HSBC's venture capital activities, tells Global Venturing it is going long on blockchain and tokenisation tech despite recent turmoil in the Web3 market.